Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | PAM | P19021 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28466214 | 0.83 | PAM (0.58) | CYP2C19PAMEGFRPPARATDP1 | |
| SCHEMBL15918919 | 0.83 | CYP17A1 (0.40) | NFKB1CYP2C19ALDH1A1KDM4E | |
| SCHEMBL15918873 | 0.83 | NFKB1 (0.42) | NFKB1NFKB2RELACYP2C19KMT2A | |
| SCHEMBL290049 | 0.79 | POLB (0.46) | CYP2C19PAMKMT2AMEN1CA1 | |
| SCHEMBL6210514 | 0.78 | MEN1 (0.58) | KMT2AMEN1ALDH1A1KDM4ETSHR | |
| SCHEMBL5727816 | 0.76 | PTPN1 (0.38) | PTPRCNFKB1NFKB2RELACYP2C19 | |
| SCHEMBL6117605 | 0.75 | MAPT (0.41) | NFKB1NFKB2RELACYP2C19MTNR1A | |
| SCHEMBL6118230 | 0.75 | MAPT (0.41) | NFKB1NFKB2RELACYP2C19MTNR1A | |
| SCHEMBL7453149 | 0.75 | NFKB1 (0.46) | NFKB1NFKB2RELAKMT2AMEN1 | |
| SCHEMBL28552314 | 0.75 | CYP2C19 (0.39) | PTPRCNFKB1NFKB2RELACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2299813-B1 | BRANCHED 3- AND 6-SUBSTITUTED QUINOLINES AS CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2015-12-16 | — | — | EP | claimed |
| US-8377955-B2 | Branched 3- and 6-substituted quinolines as CGRP receptors antagonists | Merck, Sharp & Dohme, Corp. (US) | 2013-02-19 | — | — | US | claimed |
| EP-1601674-B1 | Hydroxyalkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-08 | — | — | EP | claimed |
| JP-4712384-B2 | — | — | 2011-06-29 | — | — | JP | claimed |
| US-20110105549-A1 | BRANCHED 3- AND 6-SUBSTITUTED QUINOLINES AS CGRP RECEPTORS ANTAGONISTS | MERCK SHARP & DOHME LLC | 2011-05-05 | — | — | US | claimed |
| US-7582649-B2 | Oral administration of a dosage of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one and a carrier; opiod receptor-like-1 G-protein coupled receptor inhibitors; psychological disorders; nervous system disorders; antidiabetic agents | JANSSEN PHARMACEUTICA, NV (BE) | 2009-09-01 | — | — | US | claimed |
| US-20090124614-A1 | HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | BATTISTA KATHLEEN | 2009-05-14 | — | — | US | claimed |
| US-7081463-B2 | Hydroxy alkyl substituted 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-25 | — | — | US | claimed |
| US-20060030577-A1 | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | BATTISTA KATHLEEN | 2006-02-09 | — | — | US | claimed |
| EP-1601674-A2 | HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO 4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-12-07 | — | — | EP | claimed |
| US-20040142955-A1 | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1receptor mediated disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-07-22 | — | — | US | claimed |
| WO-2004022558-A2 | HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-03-18 | — | — | WO | claimed |
| EP-2299813-B1 | BRANCHED 3- AND 6-SUBSTITUTED QUINOLINES AS CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2015-12-16 | — | — | EP | disclosed |
| US-8778956-B2 | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-15 | — | — | US | disclosed |
| US-8377955-B2 | Branched 3- and 6-substituted quinolines as CGRP receptors antagonists | Merck, Sharp & Dohme, Corp. (US) | 2013-02-19 | — | — | US | disclosed |
| EP-1601674-B1 | Hydroxyalkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-08 | — | — | EP | disclosed |
| EP-1601674-A2 | HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO 4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-12-07 | — | — | EP | disclosed |
| CN-1694883-A | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders | JANSSEN PHARMACEUTICA NV (BE) | 2005-11-09 | — | — | CN | disclosed |
| US-20040142955-A1 | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1receptor mediated disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-07-22 | — | — | US | disclosed |
| WO-2004022558-A2 | HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142955-A1 | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1receptor mediated disorders | OPRL1, GPR4, ADRA1D | PTPRC 2819/4885NFKB1 950/4885NFKB2 1329/4885 |
| US-20060030577-A1 | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | OPRL1, ADRA1D, OPRD1 | PTPRC 3108/4885NFKB1 886/4885NFKB2 1253/4885 |
| US-20110105549-A1 | BRANCHED 3- AND 6-SUBSTITUTED QUINOLINES AS CGRP RECEPTORS ANTAGONISTS | GALR3, BDKRB2, CCKBR | PTPRC 2971/4885NFKB1 1617/4885NFKB2 2296/4885 |
| US-20090124614-A1 | HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | OPRL1, ADRA1D, OPRD1 | PTPRC 3108/4885NFKB1 886/4885NFKB2 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.